A Single-centre, Parallel-group, Randomised, Double-blind, Placebo controlled, Multiple-dose Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Apr 2018
Price : $35 *
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 13 Mar 2018 Results assessing pharmacokinetics, pharmacodynamics and safety published in the Advances in Therapy
- 22 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Aug 2014 Planned End Date changed from 1 Feb 2015 to 1 Oct 2014 as reported by ClinicalTrials.gov record.